Emcure Pharmaceuticals Ltd
EMCUREEmcure Pharmaceuticals Ltd
EMCUREPrice Chart
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
45.84 | 8.33 | — |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
51.90 | 6.61 | 0.52% |
Forecast & Ratings
Detailed Forecast from 3 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Emcure Pharmaceuticals is engaged in developing, manufacturing and marketing a range of pharmaceutical products across several therapeutic areas.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 4,274.01 | 4,911.74 | 5,130.86 | 5,067.35 | 5,918.86 | 6,031.72 | 6,715.24 | 7,355.90 | ||||||||
Raw Materials | 1,414.88 | 1,890.86 | 2,027.58 | 2,188.68 | 2,378.55 | 2,193.84 | 2,665.61 | 5,940.66 | ||||||||
Power & Fuel Cost | 83.14 | 94.47 | 100.81 | 94.85 | 97.28 | 108.58 | 120.04 | |||||||||
Employee Cost | 887.46 | 1,010.33 | 1,105.62 | 902.81 | 1,011.82 | 1,117.33 | 1,292.08 | |||||||||
Selling & Administrative Expenses | 651.74 | 684.16 | 809.58 | 403.93 | 716.19 | 840.84 | 998.47 | |||||||||
Operating & Other expenses | 542.55 | 411.47 | 404.50 | 420.10 | 321.63 | 550.19 | 362.26 | |||||||||
EBITDA | 694.24 | 820.45 | 682.77 | 1,056.98 | 1,393.39 | 1,220.94 | 1,276.78 | 1,415.24 | ||||||||
Depreciation/Amortization | 228.05 | 267.17 | 320.83 | 249.99 | 244.86 | 260.12 | 312.41 | 365.44 | ||||||||
PBIT | 466.19 | 553.28 | 361.94 | 806.99 | 1,148.53 | 960.82 | 964.37 | 1,049.80 | ||||||||
Interest & Other Items | 175.73 | 222.66 | 256.60 | 154.94 | 175.98 | 213.61 | 237.15 | 231.12 | ||||||||
PBT | 290.46 | 330.62 | 105.34 | 652.05 | 972.55 | 747.21 | 727.22 | 818.68 | ||||||||
Taxes & Other Items | 115.37 | 135.55 | 21.73 | 233.44 | 310.35 | 215.20 | 229.04 | 251.41 | ||||||||
Net Income | 175.09 | 195.07 | 83.61 | 418.61 | 662.20 | 532.01 | 498.18 | 567.27 | ||||||||
EPS | 9.68 | 10.79 | 4.62 | 23.15 | 36.62 | 29.42 | 27.52 | 31.31 | ||||||||
DPS | 3.50 | 3.50 | 0.00 | 1.00 | 3.00 | 2.00 | — | 0.00 | ||||||||
Payout ratio | 0.36 | 0.32 | 0.00 | 0.04 | 0.08 | 0.07 | 0.00 | 0.00 |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Emcure Pharmaceuticals Ltd | 52.19 | 8.33 | — |
Sun Pharmaceutical Industries Ltd | 45.10 | 6.44 | 0.75% |
Cipla Ltd | 29.41 | 4.52 | 0.87% |
Torrent Pharmaceuticals Ltd | 68.50 | 16.55 | 0.84% |
Price Comparison
Compare EMCURE with any stock or ETFShareholdings
Promoter Holdings Trend
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Decreased Total Retail Holding
In last 3 months, retail holding in the company has decreased by 3.15%
Increased Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has increased by 1.15%
Shareholding Pattern
Jul 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Increased Mutual Fund Holding
In last 3 months, mutual fund holding of the company has increased by 1.53%
Top 5 Mutual Funds holding Emcure Pharmaceuticals Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
Aditya Birla Sun Life ELSS Tax Saver Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.2314% | Percentage of the fund’s portfolio invested in the stock 0.38% | Change in the portfolio weight of the stock over the last 3 months 0.05% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 69/73 (-1) |
Mahindra Manulife Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.1969% | Percentage of the fund’s portfolio invested in the stock 1.20% | Change in the portfolio weight of the stock over the last 3 months 0.20% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 51/86 (+1) |
Bajaj Finserv Flexi Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.1636% | Percentage of the fund’s portfolio invested in the stock 1.13% | Change in the portfolio weight of the stock over the last 3 months -0.17% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 64/84 (-3) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Emcure Pharmaceuticals announced that Aravamuthan Balaji, President - IT & Digital and Senior Management Personnel of the company has resigned with effect from 31 December 2024. Powered by Capital Market - Live
Emcure Pharmaceuticals has allotted 3,33,500 equity shares under ESOS on 22 November 2024. With this allotment, the paid up equity share capital has increased to 18,94,31,847 equity shares of Rs. 10/- each aggregating to Rs. 1,89,43,18,470/']. Powered by Capital Market - Live
In Q2FY25, the drug maker's consolidated revenue from operations stood at Rs 2,002 crore, up 20.4% YoY and 10.3% QoQ. Profit after tax (PAT) was at 202 crore, up 38.2% YoY with PAT margins at 10.1%. EBITDA margins were at 20.8% with EBITDA at Rs 417 crore, up 26.1% YoY and 15.8% QoQ. Gross profit stood at Rs 1,213 crore, up 15.91% YoY and 7.18% QoQ. Gross profit margins were at 60.61% in Q2FY25, lower than 62.94% in Q2FY24 and 62.37% Q1FY25. The quarter saw strong growth especially in the International businesses that grew 25% YoY and 18% QoQ. The Canadian business continued to perform well, achieving a 51% YoY growth, driven by robust growth in its base business and its subsidiary, Mantra. The Rest of the world market business grew 29% YoY aided by strong growth in both ARV and Non-ARV segment. The company continues to see strong traction in its key focus markets. Europe experienced steady growth of 6%, driven by an increase in our base business. Emcure's domestic business grew by over 15% to Rs 933 crore, led by a steady performance in its base business and further aided by Sanofi distribution agreement. Satish Mehta, CEO and managing director, Emcure Pharmaceuticals, said, Emcure witnessed a strong performance in Q2. We have made significant investments in both our International and Domestic businesses over the past 2 years and the benefits of these efforts are starting to particularly reflect in the growth of our International business. Our recent inorganic additions ' Sanofi partnership in India and Mantra acquisition in Canada ' are now fully integrated and our focus is now on deriving both revenue and operational synergies. Moving forward, we aim to enhance the margins by leveraging operating efficiencies, while continuing to drive strong growth in both Indian and International markets through new product launches and market share gains. Pune-based Emcure Pharmaceuticals is a leading Indian pharma company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products. Shares of Emcure Pharmaceuticals were currently down 1.42% at Rs 1417. It reversed after rising as much as 6.01% in early trade today. Powered by Capital Market - Live
Net profit of Emcure Pharmaceuticals rose 39.83% to Rs 194.57 crore in the quarter ended September 2024 as against Rs 139.15 crore during the previous quarter ended September 2023. Sales rose 20.38% to Rs 2001.98 crore in the quarter ended September 2024 as against Rs 1663.09 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales2001.981663.09 20 OPM %19.0319.78 - PBDT370.31271.43 36 PBT273.41201.16 36 NP194.57139.15 40 Powered by Capital Market - Live
Emcure Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 7 November 2024Powered by Capital Market - Live
Emcure Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 7 November 2024Powered by Capital Market - Live
Emcure Pharmaceuticals announced the signing of a royalty-free voluntary licensing agreement with Gilead Sciences Ireland UC, part of California, US based Gilead Sciences to manufacture and supply generic versions of lenacapavir. This agreement is part of a broader effort to increase global access to lenacapavir for HIV prevention and treatment, with a focus on high-incidence, resource-limited countries. Emcure will play a crucial role in ensuring the availability of high-quality, low-cost versions of lenacapavir in 120 countries, primarily in low- and lower-middle-income regions. This strategic partnership underscores Emcure's commitment to innovative affordable global healthcare. Commenting on the development, Satish Mehta, Managing Director and CEO, Emcure Pharmaceuticals, said, We are proud to partner with Gilead in this global initiative to expand access to critical HIV medicines. As the leader in HIV antiviral segment in covered market in India with long standing experience in supplying HIV medicines to over 100 LMIC countries, Emcure is uniquely positioned to drive impactful change in the global fight against HIV. By bringing lenacapavir to the regions that need it most, we are taking a step forward in improving health outcomes worldwide. Powered by Capital Market - Live
Net profit of Emcure Pharmaceuticals rose 10.48% to Rs 144.08 crore in the quarter ended June 2024 as against Rs 130.41 crore during the previous quarter ended June 2023. Sales rose 16.64% to Rs 1815.14 crore in the quarter ended June 2024 as against Rs 1556.16 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales1815.141556.16 17 OPM %18.5319.00 - PBDT301.00258.52 16 PBT207.41191.34 8 NP144.08130.41 10 Powered by Capital Market - Live
Emcure Pharmaceuticals has received upgrade in credit ratings from CRISIL for bank facilities of Rs 2,475.43 crore of the company as under: Long term rating - CRISIL AA-/ Stable Short term rating - CRISIL A1+Powered by Capital Market - Live
Emcure Pharmaceuticals announced that CARE Ratings has upgraded the credit ratings assigned to bank facilities of the company as under: Long term bank facilities (Rs 557.50 crore) - CARE AA-; Stable Long term / short term bank facilities (Rs 1,286 crore) - CARE AA-; Stable/ CARE A1+ Short term bank facilities (Rs 114 crore) - CARE A1+Powered by Capital Market - Live
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 6.45%, vs industry avg of 9.03%
Decreasing Market Share
Over the last 5 years, market share decreased from 2.24% to 1.78%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 20.63%, vs industry avg of 15.27%